<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-title>Retrovirology</journal-title><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1742-4690-5-67</article-id><article-id pub-id-type="pmid">18638397</article-id><article-id pub-id-type="doi">10.1186/1742-4690-5-67</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title>Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Caly</surname><given-names>Leon</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>leon.caly@med.monash.edu.au</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Saksena</surname><given-names>Nitin K</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>nitin_saksena@wmi.usyd.edu.au</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Piller</surname><given-names>Sabine C</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>S.Piller@uws.edu.au</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Jans</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>david.jans@med.monash.edu.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia</aff><aff id="I2"><label>2</label>Retroviral Genetics Division, Centre for Virus Research, Westmead Millennium Institute, Westmead Hospital, The University of Sydney, Darcy Road, Westmead, N.S.W 2145, Australia</aff><aff id="I3"><label>3</label>HIV Protein Function and Interactions Group, Centre for Virus Research, Westmead Millennium Institute, Westmead Hospital, The University of Sydney, Darcy Road, Westmead, N.S.W 2145, Australia</aff><aff id="I4"><label>4</label>University of Western Sydney, Penrith South DC, N.S.W 1797, Australia</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>18</day><month>7</month><year>2008</year></pub-date><volume>5</volume><fpage>67</fpage><lpage>67</lpage><ext-link ext-link-type="uri" xlink:href="http://www.retrovirology.com/content/5/1/67"/><history><date date-type="received"><day>18</day><month>1</month><year>2008</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Caly et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Caly et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Caly Leon leon.caly@med.monash.edu.au </dc:author><dc:title> Impaired nuclear import and viral incorporation of Vpr derived from a HIV long-term non-progressor </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Retrovirology 5(1): 67-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-4690(2008)5:1&#x0003c;67&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-4690</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>We previously reported an epidemiologically linked HIV-1 infected patient cohort in which a long-term non-progressor (LTNP) infected two recipients who then exhibited normal disease progression. Expression of patient-derived <italic>vpr </italic>sequences from each of the three cohort members in mammalian cells tagged with GFP revealed a significant reduction in Vpr nuclear import and virion incorporation uniquely from the LTNP, whereas Vpr from the two progressing recipients displayed normal localisation and virion incorporation, implying a link between efficient Vpr nuclear import and HIV disease progression. Importantly, an F72L point mutation in the LTNP was identified for the first time as being uniquely responsible for decreased Vpr nuclear import.</p></abstract></article-meta></front><body><sec><title>Findings</title><p>The highly conserved HIV accessory protein Viral Protein R (Vpr) is vital for HIV infection and replication <italic>in vivo</italic>, particularly within non-dividing cells, including terminally differentiated T-cells and macrophages where nuclear envelope integrity is permanently maintained [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. On its own and within the context of HIV infection [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>], Vpr has been shown to localize to the nucleus and induce G<sub>2 </sub>cell-cycle arrest through hyperphosphorylation of p34-cdc2, which provides the most optimal environment for viral replication [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B13">13</xref>], followed closely by apoptosis [<xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. During HIV infection, Vpr associates with the viral cDNA containing Pre-integration Complex (PIC) increasing its affinity for components of the cellular nuclear import machinery [<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B25">25</xref>] through the activity of 2 distinct nuclear localization signals (NLSs) within its N- [<xref ref-type="bibr" rid="B26">26</xref>] and C-termini [<xref ref-type="bibr" rid="B27">27</xref>], thus driving productive HIV infection.</p><p>We previously reported [<xref ref-type="bibr" rid="B28">28</xref>] on a cohort spanning 1992 to 2000, comprising an HIV<sup>+ </sup>long-term non-progressor (LTNP) (donor A) and two recipients (B and C) who upon transmission (autumn and summer 1989 respectively) from donor A progressed to AIDS. <italic>Vpr </italic>sequences derived from HIV pro-viral DNA isolated from PBMCs as well as circulating virus, revealed that sequences from the progressing recipients differed markedly to those of the LTNP founder virus host, providing the first evidence for Vpr positive selection during disease progression in an epidemiologically-linked cohort (see also [<xref ref-type="bibr" rid="B29">29</xref>]).</p><p>In this study, cohort-derived GFP-Vpr mammalian cell expression vectors were used to investigate Vpr subcellular localisation and nuclear import. In total, 4 HIV-1 <italic>vpr </italic>clones were isolated from donor A (A1, A3, A5 and A6 corresponding to years 1996, 1998, 1999 and 2000), 4 from recipient B (B3, B4, B5 and B6 corresponding to years 1997, 1998, 1998 and 1999) and 7 from recipient C (C2, C3, C5, C6, C8, C10 and C11 from 1992, 1992, 1993, 1994, 1994, 1998 and 1999 respectively) and used to generate the GFP-Vpr expression constructs. Lipofectamine&#x02122; 2000 (Invitrogen) was used to transfect constructs into HeLa and COS-7 (<italic>not shown</italic>) cells, followed by imaging 14 hours post transfection using an Olympus FV-1000 confocal laser scanning microscope (CLSM), with similar results. Initial analysis of late-stage <italic>vpr </italic>gene products from all 3 donors revealed a reduction in nuclear fluorescence accompanied by perinuclear accumulation for LTNP sample A6-2 (patient <bold>A</bold>, time-point <bold>6</bold>, clone <bold>#2</bold>) (Fig. <xref ref-type="fig" rid="F1">1A</xref>(iii)) compared to pUC18-NL4.3 derived [<xref ref-type="bibr" rid="B30">30</xref>] wild-type GFP-Vpr<sup>1&#x02013;96 </sup>(Fig. <xref ref-type="fig" rid="F1">1A</xref>(ii)): a phenotype not observed in samples from patients B (B6-4) nor C (C11-1) (Fig <xref ref-type="fig" rid="F1">1A</xref>(iv, v)). Quantification of nuclear import was determined using ImageJ analysis software [<xref ref-type="bibr" rid="B31">31</xref>] where the ratio of nuclear (Fn) to cytoplasmic (Fc) fluorescence, subtracting background (B) was calculated, Fn/c = (Fn-B)/(Fc-B). A highly significant (p &#x0003c; 0.0001) reduction in Fn/c was observed between GFP-Vpr<sup>1&#x02013;96 </sup>(Fn/c ~2.4) and GFP-Vpr<sup>A6-2 </sup>(Fn/c ~0.9) indicating a reduction in nuclear accumulation. No significant difference in Fn/c was observed between GFP-Vpr<sup>1&#x02013;96 </sup>and GFP-Vpr<sup>B6-4 </sup>or GFP-Vpr<sup>C11-1 </sup>(Fig. <xref ref-type="fig" rid="F1">1B</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Late-stage LTNP-derived GFP-Vpr samples show decreased levels of nuclear accumulation compared to wildtype Vpr and progressing donors B and C</bold>. <bold>(A) </bold>HeLa cells were transfected with indicated GFP-Vpr constructs using Lipofectamine 2000&#x02122; with confocal images obtained 14 hours later using an Olympus FV1000 CLSM. <bold>(B) </bold>Analysis of CLSM images (as per <bold>A</bold>) with ImageJ was performed to determine the Fn/c. As a whole, late-stage samples from patient A (A6-2, A6-3, A6-4) and the Vpr (F72L) point mutant displayed significantly (p &#x0003c; 0.0001) reduced Fn/c ratios compared to wildtype Vpr. <bold>(C) </bold>Sequence analysis of patient-derived <italic>vpr </italic>sequences identifies F72L substitution mutation (as indicated) uniquely within all GFP-Vpr constructs with reduced nuclear accumulation.</p></caption><graphic xlink:href="1742-4690-5-67-1"/></fig><p>To establish if decreased Vpr nuclear accumulation was a specifically conserved viral feature of the LTNP or an acquired trait, GFP-Vpr constructs from early-cohort timepoints were analysed. Samples from 1996 (GFP-Vpr<sup>A1-2</sup>) and 1998 (GFP-Vpr<sup>A3-1</sup>) (Fig. <xref ref-type="fig" rid="F1">1A</xref>(vi, vii)) both displayed levels of nuclear accumulation comparable to wildtype GFP-Vpr<sup>1&#x02013;96 </sup>(Fig. <xref ref-type="fig" rid="F1">1B</xref>), implying that loss of nuclear import occurred post 1998.</p><p>With the loss of efficient nuclear accumulation identified as a late-stage LTNP trait, further analysis of late-stage clones A6-3 and A6-5 (<italic>clone A6-5 data not shown as sequence is homologous to A6-3</italic>) was performed, revealing Fn/c values significantly lower than wildtype GFP-Vpr<sup>1&#x02013;96 </sup>(Fig. <xref ref-type="fig" rid="F1">1B</xref>). Of interest, a single late-stage clone (GFP-Vpr<sup>A6-4</sup>) displayed a small degree of nuclear accumulation (Fig. <xref ref-type="fig" rid="F1">1A</xref>(ix)), although at levels significantly reduced compared to wildtype (Fig. <xref ref-type="fig" rid="F1">1B</xref>). Sequence analysis revealed that all clones with reduced nuclear accumulation (Vpr<sup>A6-2 </sup>and Vpr<sup>A6-3/5</sup>) contained a phenylalanine to leucine mutation at amino acid position 72 (F72L) (Fig. <xref ref-type="fig" rid="F1">1C</xref>). This mutation is absent in the nuclear localizing Vpr<sup>A6-4</sup>, which is otherwise identical in sequence to late-stage samples Vpr<sup>A6-3/5</sup>. Analysis of our database containing over 1200 published and unpublished Vpr sequences revealed that the F72L mutation has only been reported once previously [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>To determine the specific role of F72L in abrogation of Vpr nuclear import, an F72L substitution was engineered into wildtype Vpr and an expression construct (GFP-Vpr<sup>F72L</sup>) produced. Subsequent transfection (Fig. <xref ref-type="fig" rid="F1">1A</xref>(x)) revealed a reduction in GFP-Vpr<sup>F72L </sup>nuclear accumulation when compared with wildtype GFP-Vpr<sup>1&#x02013;96 </sup>(Fig. <xref ref-type="fig" rid="F1">1A</xref>(ii)), in a similar fashion to clinically derived GFP-Vpr<sup>A6-2 </sup>(Fig. <xref ref-type="fig" rid="F1">1B</xref>), thus confirming F72L as a probable mechanism for the observed reduction in nuclear accumulation within late-stage LTNP samples. This reduction in nuclear import was accompanied by an accumulation of GFP-Vpr protein within the perinuclear region of the cell, concordant with an area encompassing the proposed location of the Golgi. Colocalisation studies with the Golgi-specific marker protein &#x003b3;-adaptin revealed that Vpr proteins harbouring the F72L point mutation, but not those with wildtype phenylalanine, were localized to the Golgi apparatus, implying that reduced nuclear accumulation could in part be attributed to this mislocalisation of GFP-Vpr (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). The lack of colocalisation between F72L-containing Vpr proteins and the endoplasmic reticulum (ER) marker Calnexin (Sigma, C-4731), confirmed that Vpr mislocalisation to the Golgi is not a result of general mistargeting (see Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>).</p><p>Although the precise pathways involved are still debated, efficient nuclear export [<xref ref-type="bibr" rid="B33">33</xref>] and/or cytoplasmic retention [<xref ref-type="bibr" rid="B34">34</xref>] of Vpr during viral infection has been identified as a key requirement for virion incorporation. With this in mind, we assessed the ability of nuclear import-inhibited cytosolic GFP-Vpr<sup>F72L </sup>to incorporate into forming virions. Briefly, 293T cells were cotransfected with a panel of GFP-Vpr expression vectors as well as the proviral plasmid pUC18-NL4.3, with the resultant virions analysed by Western blotting for GFP-Vpr incorporation. Interestingly we found that all F72L-containing GFP-Vpr proteins that failed to significantly localize within the nucleus, were absent from purified viral lysates (Fig. <xref ref-type="fig" rid="F2">2A</xref>), implying a possible link between the efficient nuclear transport of Vpr and virion incorporation. To examine the effect of the F72L mutation on HIV infectivity, we infected &#x003b3;-irradiated, non-dividing CD4<sup>+ </sup>MAGI (<underline>M</underline>ultinuclear <underline>A</underline>ctivation of a <underline>G</underline>alactosidase <underline>I</underline>ndicator) cells which contain an integrated HIV-1-LTR-&#x003b2;-galactosidase gene with virus derived from 293T cells cotransfected with &#x00394;Vpr pro-virus and wildtype or F72L-containing GFP-Vpr encoding plasmids. 48 hours post infection, MAGI cells were fixed and stained with 5-bromo-4-chloro-3-indolyl-beta-Dgalactopyranoside (X-gal) [<xref ref-type="bibr" rid="B35">35</xref>], followed by scoring for infected cells (blue nuclei) due to LTR-&#x003b2;-gal transactivation by viral Tat protein. Virus derived from all F72L-containing plasmids showed a significant (p &#x0003c; 0.0001), 5-fold reduction in viral infectivity when compared to wildtype Vpr<sup>1&#x02013;96 </sup>(Fig. <xref ref-type="fig" rid="F2">2B</xref>). This dramatic reduction in infectivity presumably stems from the lack of virion incorporation of F72L-containing Vpr (Fig. <xref ref-type="fig" rid="F2">2A</xref>) and resultant absence of Vpr-facilitated PIC nuclear import, a key factor in efficient HIV replication within non-dividing cells [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B36">36</xref>].</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>F72L-containing GFP-Vpr proteins fail to incorporate into forming virions, which show decreased infectivity of non-dividing MAGI (Multinuclear Activation of a Galactosidase Indicator) cells correlating with reduced importin-&#x003b2;3 binding</bold>. <bold>(A</bold>) Virus was derived from 293T cells cotransfected with pEPI-GFP-Vpr and proviral plasmid pUC18-NL4.3 and subjected to Western blot analysis, revealing the absence of GFP-Vpr protein in F72L containing samples. Control staining for p24 capsid protein indicates the presence of virus in all samples (*denotes lack of virion incorporation). <bold>(B) </bold>Virus derived from 293T cells cotransfected with the &#x00394;Vpr pro-viral plasmid pUC18-NL4.3(FS) and pEPI-GFP-Vpr (1&#x02013;96, A6-2, A6-3 or F72L) was purified, normalized using an RT assay and used to infect growth arrested (&#x003b3;-irradiated, 2 cycles at 30 Gy) MAGI (CD4<sup>+</sup>, integrated HIV-1-LTR-&#x003b2;-gal) cells. 48 hours post infection cells were fixed (1% formaldehyde/0.2% glutaraldehyde/PBS), stained (4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 2 mM MgCl<sub>2</sub>, 0.4 mg/ml 5-bromo-4-chloro-3-indolyl-&#x003b2;-D-galactopyranoside [X-gal]) and scored for viral infectivity. Infected cells display X-gal stained (blue) nuclei due to expression of the early HIV protein Tat, which binds the HIV-LTR promoter of the integrated &#x003b2;-gal gene, resulting in expression of the &#x003b2;-gal protein. Non-infected cells remain colourless due to the lack of Tat expression and subsequent activation of the &#x003b2;-gal gene. Data presented depicts relative levels of infectivity (% +/- SEM) compared to wildtype Vpr<sup>1&#x02013;96</sup>. Virus derived from F72L-cotransfected 293T cells displayed a significant (p &#x0003c; 0.0001) 5-fold reduction in viral infectivity of non-dividing cells compared to wildtype Vpr<sup>1&#x02013;96</sup>. <bold>(C) </bold>Native PAGE gel-shift mobility assay; 2 &#x003bc;M GFP-Vpr<sup>1&#x02013;96 </sup>or GFP alone was incubated with 10 &#x003bc;M importin-&#x003b1;2, -&#x003b2;1, -&#x003b1;2/&#x003b2;1 or -&#x003b2;3 as indicated. <bold>(D) </bold>Native PAGE gel-shift mobility titration assay; (i) 2 &#x003bc;M GFP-Vpr<sup>1&#x02013;96 </sup>or GFP-Vpr<sup>F72L </sup>was incubated with increasing concentrations of Importin-&#x003b2;3 protein as indicated. (ii) Fluorimetric analysis of gel-shift assays from D(i), was performed as per [<xref ref-type="bibr" rid="B39">39</xref>] with the binding curves generated used to calculate dissociation constants (<italic>K</italic><sub>d</sub>). <bold>(E)i </bold>Typical CLSM images of fixed COS-7 cells expressing the indicated GFP-fusion proteins alone or in the context of c-myc-tagged-human Importin-&#x003b2;3. Cells were permeabilised and stained 14 hours post transfection with anti-c-myc antibody (Sigma) and visualized with Alexa-Fluo-568 (Molecular Probes). <bold>(E)ii </bold>Analysis of CLSM images (as per <bold>E(i)</bold>) with ImageJ was performed to determine the Fn/c. Exogenous Importin-&#x003b2;3 was found to significantly (p = 0.0378) increase the nuclear accumulation of wildtype GFP-Vpr<sup>1&#x02013;96</sup>, but not that of GFP-Vpr<sup>F72L </sup>or F72L containing GFP-Vpr<sup>A6-3</sup>.</p></caption><graphic xlink:href="1742-4690-5-67-2"/></fig><p>Nuclear accumulation of Vpr is governed by 2 distinct NLSs; a leucine-rich N-terminal &#x003b1;-helix (<sup>20</sup>LELLEEL<sup>26</sup>) which has been linked to virion incorporation [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>], and a C-terminal arginine-rich bipartite (<underline>underlined</underline>) (<sup>71</sup>H<bold>F</bold><underline>RI</underline>G<underline>C</underline>RHSRIGVT<underline>RQRR</underline>A<underline>R</underline><sup>90</sup>) NLS [<xref ref-type="bibr" rid="B27">27</xref>] which incorporates phenylalanine 72 (bold). To determine if the identified F72L substitution affects the function of Vpr's C-terminal NLS, we used a previously described fluorescence based gel-shift mobility assay [<xref ref-type="bibr" rid="B39">39</xref>] to compare the interaction between wildtype GFP-Vpr<sup>1&#x02013;96 </sup>and GFP-Vpr<sup>F72L </sup>with a panel of purified importin proteins. We established that wildtype GFP-Vpr<sup>1&#x02013;96 </sup>was able to bind with high affinity to human Importin-&#x003b2;3 (h&#x003b2;3) but not other members of the importin superfamily, including Importin-&#x003b2;1, Importin-&#x003b1;2 or the Importin-&#x003b1;2/&#x003b2;1 heterodimer. (Fig. <xref ref-type="fig" rid="F2">2C</xref>). Titrations revealed that GFP-Vpr<sup>F72L </sup>was unable to bind h&#x003b2;3 as effectively as wildtype GFP-Vpr<sup>1&#x02013;96 </sup>(K<sub>d </sub>= 0.66 &#x003bc;M vs. 1.60 &#x003bc;M) (Fig. <xref ref-type="fig" rid="F2">2D</xref>(i, ii)), indicating a direct relationship between F72L and decreased Importin-&#x003b2;3 binding capacity. <italic>In vivo </italic>cotransfection of GFP-Vpr constructs with Importin-&#x003b2;3 was found to increase the Fn/c of wildtype GFP-Vpr<sup>1&#x02013;96</sup>, but not that of GFP-Vpr<sup>F72L </sup>or GFP-Vpr<sup>A6-3</sup>, consistent with the idea that Importin-&#x003b2;3 contributes to nuclear import of Vpr, and that the F72L mutation impacts on recognition by Importin-&#x003b2;3 directly (see Fig. <xref ref-type="fig" rid="F2">2E</xref>(i, ii)). We therefore propose that the F72L mutation itself leads to decreased Vpr nuclear import and consequently reduced virion incorporation due to reduced binding efficiency to Importin-&#x003b2;3.</p><p>It does not seem unreasonable to speculate that <italic>in vivo </italic>selective pressures have driven the evolution of functionally-attenuated <italic>vpr </italic>to ensure long-term viral survival and replication <italic>in vivo </italic>[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B42">42</xref>]. Our study shows that F72L-containing Vpr does not accumulate within host cell nuclei or incorporate into nascent virions; subsequent infections with such a Vpr-deficient virus are less efficient, leading to reduced virus production [<xref ref-type="bibr" rid="B41">41</xref>-<xref ref-type="bibr" rid="B43">43</xref>] and ultimately a lack of deterioration in T-cell numbers, as in the case of the LTNP. Many of our observations are concordant with analysis of LTNP infection status in 2000, which revealed normal CD4<sup>+ </sup>T-cell levels (&#x0003e;550 cells per &#x003bc;l) suggesting the absence of significant HIV-mediated T-cell targeting and depletion. Since our data here suggests that c. 75% of late-stage proviral strains in the LTNP would produce virions lacking Vpr due to the F72L mutation, the levels of observed CD4<sup>+ </sup>T-cells within the LTNP may be due to the inability of HIV lacking Vpr to import the viral genome into the non-dividing host cell nucleus and carry out subsequent steps of infection [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Presumably one advantage for the virus is that the preservation of patient health status leads to enhanced probability of transmission to new hosts, thus leading to increased virus spread. Low levels of virus production (&#x0003c;425 HIV copies/ml plasma) [<xref ref-type="bibr" rid="B29">29</xref>] are presumably maintained through the activity of a small subset of Vpr quasi-species that do not contain the F72L mutation (A6-4) or perhaps viruses that we were unable to characterize due to their low prevalence. Additional to all of the above considerations, it is important to remember that the effects of decreased Vpr nuclear import through the F72L mutation are likely to be influenced by many other factors, including host genetic make-up and immune response, which in themselves can influence disease progression [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B45">45</xref>-<xref ref-type="bibr" rid="B49">49</xref>].</p><p>In summary this study provides evidence for a naturally occurring Vpr mutation within an epidemiologically-linked cohort and its possible contribution to non-progressive HIV disease status through disruption of efficient nuclear transport and apparent lack of viral incorporation, leading to reduced infectivity of non-dividing cells (Fig. <xref ref-type="fig" rid="F2">2B</xref>). To demonstrate formally the link between Vpr nuclear localisation and disease progression, further analysis of Vpr<sup>F72L </sup>in a HIV infectious system is required, eg. to dismiss the possibility that the effects in terms of lack of assembly of Vpr<sup>F72L </sup>may in part be due to impaired p6gag binding, stemming from conformational or other effects. With this proviso in mind, however, the work here and elsewhere (see also [<xref ref-type="bibr" rid="B50">50</xref>]) implies that functional selection of <italic>vpr </italic>viral quasispecies in concert with host selection pressure over time, as evident in the LTNP, may be a factor in determining the rate of disease progression.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>LTNP derived Vpr proteins with reduced nuclear accumulation localize within the Golgi</bold>. Typical CLSM images of fixed COS-7 cells expressing the indicated GFP-fusion proteins. Cells were permeabilised and stained 14 hours post transfection for &#x003b3;-adaptin and visualized with Alexa-Fluor-568. GFP-Vpr proteins specifically containing F72L show colocalisation with the Golgi apparatus as indicated by arrows.</p></caption><media xlink:href="1742-4690-5-67-S1.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>LTNP derived Vpr proteins with reduced nuclear accumulation localize within the Golgi</bold>. Typical CLSM images of fixed COS-7 cells expressing the indicated GFP-fusion proteins. Cells were permeabilised and stained 14 hours post transfection for Calnexin and visualized with Alexa-Fluor-568. GFP-Vpr was found to not localize within the ER.</p></caption><media xlink:href="1742-4690-5-67-S2.ppt" mimetype="application" mime-subtype="vnd.ms-powerpoint"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>Bin Wang and Meriet Mikhail (Millennium Institute), and Michael Gill and Brenda Beckthold (University of Calgary) are acknowledged for providing the samples from the cohort patients that were used for our published study [<xref ref-type="bibr" rid="B28">28</xref>], on which the present work builds. Part of the work was funded by NHMRC project grant #222744 to SCP and DAJ, and NHMRC Senior fellowship #384109 to DAJ.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinzinger</surname><given-names>NK</given-names></name><name><surname>Bukinsky</surname><given-names>MI</given-names></name><name><surname>Haggerty</surname><given-names>SA</given-names></name><name><surname>Ragland</surname><given-names>AM</given-names></name><name><surname>Kewalramani</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Ratner</surname><given-names>L</given-names></name><name><surname>Stevenson</surname><given-names>M</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><article-title>The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in non-dividing host cells</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>7311</fpage><lpage>7315</lpage><pub-id pub-id-type="pmid">8041786</pub-id><pub-id pub-id-type="doi">10.1073/pnas.91.15.7311</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iijima</surname><given-names>S</given-names></name><name><surname>Nitahara-Kasahara</surname><given-names>Y</given-names></name><name><surname>Kimata</surname><given-names>K</given-names></name><name><surname>Zhong Zhuang</surname><given-names>W</given-names></name><name><surname>Kamata</surname><given-names>M</given-names></name><name><surname>Isogai</surname><given-names>M</given-names></name><name><surname>Miwa</surname><given-names>M</given-names></name><name><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></name><name><surname>Aida</surname><given-names>Y</given-names></name></person-group><article-title>Nuclear localization of Vpr is crucial for the efficient replication of HIV-1 in primary CD4+ T cells</article-title><source>Virology</source><year>2004</year><volume>327</volume><fpage>249</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">15351213</pub-id><pub-id pub-id-type="doi">10.1016/j.virol.2004.06.024</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Le Rouzic</surname><given-names>E</given-names></name><name><surname>Benichou</surname><given-names>S</given-names></name></person-group><article-title>The Vpr protein from HIV-1: distinct roles along the viral life cycle</article-title><source>Retrovirology</source><year>2005</year><volume>2</volume><fpage>11</fpage><pub-id pub-id-type="pmid">15725353</pub-id><pub-id pub-id-type="doi">10.1186/1742-4690-2-11</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>DN</given-names></name><name><surname>Refaeli</surname><given-names>Y</given-names></name><name><surname>MacGregor</surname><given-names>RR</given-names></name><name><surname>Weiner</surname><given-names>DB</given-names></name></person-group><article-title>Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>10873</fpage><lpage>10877</lpage><pub-id pub-id-type="pmid">7971975</pub-id><pub-id pub-id-type="doi">10.1073/pnas.91.23.10873</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rucker</surname><given-names>E</given-names></name><name><surname>Grivel</surname><given-names>JC</given-names></name><name><surname>Munch</surname><given-names>J</given-names></name><name><surname>Kirchhoff</surname><given-names>F</given-names></name><name><surname>Margolis</surname><given-names>L</given-names></name></person-group><article-title>Vpr and Vpu are important for efficient human immunodeficiency virus type 1 replication and CD4+ T-cell depletion in human lymphoid tissue ex vivo</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>12689</fpage><lpage>12693</lpage><pub-id pub-id-type="pmid">15507658</pub-id><pub-id pub-id-type="doi">10.1128/JVI.78.22.12689-12693.2004</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>Y</given-names></name><name><surname>McEntee</surname><given-names>M</given-names></name><name><surname>Weis</surname><given-names>K</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><article-title>Characterization of HIV-1 vpr nuclear import: analysis of signals and pathways</article-title><source>J Cell Biol</source><year>1998</year><volume>143</volume><fpage>875</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">9817747</pub-id><pub-id pub-id-type="doi">10.1083/jcb.143.4.875</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Ratner</surname><given-names>L</given-names></name></person-group><article-title>Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest</article-title><source>Virology</source><year>1998</year><volume>242</volume><fpage>414</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">9514978</pub-id><pub-id pub-id-type="doi">10.1006/viro.1998.9028</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>S</given-names></name><name><surname>Khalili</surname><given-names>K</given-names></name><name><surname>Sawaya</surname><given-names>BE</given-names></name></person-group><article-title>Effect of HIV-1 Vpr on cell cycle regulators</article-title><source>DNA Cell Biol</source><year>2004</year><volume>23</volume><fpage>249</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">15142382</pub-id><pub-id pub-id-type="doi">10.1089/104454904773819833</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elder</surname><given-names>RT</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Yanagida</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25</article-title><source>Virology</source><year>2001</year><volume>287</volume><fpage>359</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">11531413</pub-id><pub-id pub-id-type="doi">10.1006/viro.2001.1007</pub-id></citation></ref><ref id="B10"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>N</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Yamazaki</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>J-I</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name></person-group><article-title>HIV-1 Vpr induces G2 cell cycle arrest in fission yeast associated with Rad24/14-3-3-dependent, Chk1/Cds1-independent Wee1 upregulation</article-title><source>Microbes Infect</source><year>2006</year><fpage>1</fpage><lpage>9</lpage></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshizuka</surname><given-names>N</given-names></name><name><surname>Yoshizuka-Chadani</surname><given-names>Y</given-names></name><name><surname>Krishnan</surname><given-names>V</given-names></name><name><surname>Zeichner</surname><given-names>SL</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 Vpr-dependent cell cycle arrest through a mitogen-activated protein kinase signal transduction pathway</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>11366</fpage><lpage>11381</lpage><pub-id pub-id-type="pmid">16103188</pub-id><pub-id pub-id-type="doi">10.1128/JVI.79.17.11366-11381.2005</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>ES</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>JL</given-names></name><name><surname>Ardon</surname><given-names>O</given-names></name><name><surname>Dehart</surname><given-names>JL</given-names></name><name><surname>Blackett</surname><given-names>J</given-names></name><name><surname>Choudhary</surname><given-names>SK</given-names></name><name><surname>Camerini</surname><given-names>D</given-names></name><name><surname>Nghiem</surname><given-names>P</given-names></name><name><surname>Planelles</surname><given-names>V</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>9286</fpage><lpage>9294</lpage><pub-id pub-id-type="pmid">15485898</pub-id><pub-id pub-id-type="doi">10.1128/MCB.24.21.9286-9294.2004</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>ES</given-names></name><name><surname>Sherman</surname><given-names>MP</given-names></name><name><surname>Blackett</surname><given-names>JL</given-names></name><name><surname>Neidleman</surname><given-names>JA</given-names></name><name><surname>Kreis</surname><given-names>C</given-names></name><name><surname>Mundt</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>SA</given-names></name><name><surname>Warmerdam</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>J</given-names></name><name><surname>Hecht</surname><given-names>FM</given-names></name><name><surname>Grant</surname><given-names>RM</given-names></name><name><surname>de Noronha</surname><given-names>CM</given-names></name><name><surname>Weyrich</surname><given-names>AS</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name><name><surname>Planelles</surname><given-names>V</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo</article-title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>10407</fpage><lpage>10418</lpage><pub-id pub-id-type="pmid">16956949</pub-id><pub-id pub-id-type="doi">10.1128/JVI.01212-06</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>JL</given-names></name><name><surname>Dehart</surname><given-names>JL</given-names></name><name><surname>Zimmerman</surname><given-names>E</given-names></name><name><surname>Ardon</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>B</given-names></name><name><surname>Jacquot</surname><given-names>G</given-names></name><name><surname>Benichou</surname><given-names>S</given-names></name><name><surname>Planelles</surname><given-names>V</given-names></name></person-group><article-title>HIV-1 Vpr-induced Apoptosis Is Cell Cycle Dependent and Requires Bax but Not ANT</article-title><source>PLoS Pathog</source><year>2006</year><volume>2</volume><fpage>1106</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0020127</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>JL</given-names></name><name><surname>Zimmerman</surname><given-names>ES</given-names></name><name><surname>DeHart</surname><given-names>JL</given-names></name><name><surname>Murala</surname><given-names>S</given-names></name><name><surname>Ardon</surname><given-names>O</given-names></name><name><surname>Blackett</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Planelles</surname><given-names>V</given-names></name></person-group><article-title>ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis</article-title><source>Cell Death &#x00026; Differentiation</source><year>2005</year><volume>12</volume><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">15650754</pub-id><pub-id pub-id-type="doi">10.1038/sj.cdd.4401565</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arunagiri</surname><given-names>C</given-names></name><name><surname>macreadie</surname><given-names>I</given-names></name><name><surname>Hewish</surname><given-names>D</given-names></name><name><surname>Azad</surname><given-names>A</given-names></name></person-group><article-title>A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes</article-title><source>Apoptosis</source><year>1997</year><volume>2</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">14646566</pub-id><pub-id pub-id-type="doi">10.1023/A:1026487609215</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borgne-Sanchez</surname><given-names>A</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Langonne</surname><given-names>A</given-names></name><name><surname>Baux</surname><given-names>L</given-names></name><name><surname>Lecoeur</surname><given-names>H</given-names></name><name><surname>Chauvier</surname><given-names>D</given-names></name><name><surname>Lassalle</surname><given-names>M</given-names></name><name><surname>Deas</surname><given-names>O</given-names></name><name><surname>Briere</surname><given-names>J-J</given-names></name><name><surname>Brabant</surname><given-names>M</given-names></name><name><surname>Roux</surname><given-names>P</given-names></name><name><surname>Pechoux</surname><given-names>C</given-names></name><name><surname>Briand</surname><given-names>J-P</given-names></name><name><surname>Hoebeke</surname><given-names>J</given-names></name><name><surname>Deniaud</surname><given-names>A</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name><name><surname>Rustin</surname><given-names>P</given-names></name><name><surname>Edelman</surname><given-names>L</given-names></name><name><surname>Rebouillat</surname><given-names>D</given-names></name><name><surname>Jacotot</surname><given-names>E</given-names></name></person-group><article-title>Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of &#x003b1;v&#x003b2;3-expressing endothelial cells</article-title><source>Cell Death Differ</source><year>2006</year><volume>14</volume><fpage>422</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">16888644</pub-id><pub-id pub-id-type="doi">10.1038/sj.cdd.4402018</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boya</surname><given-names>P</given-names></name><name><surname>Pauleau</surname><given-names>AL</given-names></name><name><surname>Poncet</surname><given-names>D</given-names></name><name><surname>Gonzalez-Polo</surname><given-names>RA</given-names></name><name><surname>Zamzami</surname><given-names>N</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Viral proteins targeting mitochondria: controlling cell death</article-title><source>Biochim Biophys Acta</source><year>2004</year><volume>1659</volume><fpage>178</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">15576050</pub-id><pub-id pub-id-type="doi">10.1016/j.bbabio.2004.08.007</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaynor</surname><given-names>EM</given-names></name><name><surname>Chen</surname><given-names>IS</given-names></name></person-group><article-title>Analysis of apoptosis induced by HIV-1 Vpr and examination of the possible role of the hHR23A protein</article-title><source>Exp Cell Res</source><year>2001</year><volume>267</volume><fpage>243</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">11426943</pub-id><pub-id pub-id-type="doi">10.1006/excr.2001.5247</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>CA</given-names></name><name><surname>Mukhtar</surname><given-names>M</given-names></name><name><surname>Pomerantz</surname><given-names>RJ</given-names></name></person-group><article-title>Human Immunodeficiency Virus Type 1 Vpr Induces Apoptosis in Human Neuronal Cells</article-title><source>J Virol</source><year>2000</year><volume>74</volume><fpage>9717</fpage><lpage>9726</lpage><pub-id pub-id-type="pmid">11000244</pub-id><pub-id pub-id-type="doi">10.1128/JVI.74.20.9717-9726.2000</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waldhuber</surname><given-names>MG</given-names></name><name><surname>Bateson</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>Greenway</surname><given-names>AL</given-names></name><name><surname>McPhee</surname><given-names>DA</given-names></name></person-group><article-title>Studies with GFP-Vpr fusion proteins: induction of apoptosis but ablation of cell-cycle arrest despite nuclear membrane or nuclear localization</article-title><source>Virology</source><year>2003</year><volume>313</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">12951024</pub-id><pub-id pub-id-type="doi">10.1016/S0042-6822(03)00258-7</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>D</given-names></name><name><surname>Vodicka</surname><given-names>MA</given-names></name><name><surname>Lucero</surname><given-names>G</given-names></name><name><surname>Svitkina</surname><given-names>TM</given-names></name><name><surname>Borisy</surname><given-names>GG</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Hope</surname><given-names>TJ</given-names></name></person-group><article-title>Visualization of the intracellular behavior of HIV in living cells</article-title><source>J Cell Biol</source><year>2002</year><volume>159</volume><fpage>441</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">12417576</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200203150</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piller</surname><given-names>SC</given-names></name><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name></person-group><article-title>Nuclear import of the pre-integration complex (PIC): the Achilles heel of HIV?</article-title><source>Curr Drug Targets</source><year>2003</year><volume>4</volume><fpage>409</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">12816349</pub-id><pub-id pub-id-type="doi">10.2174/1389450033490984</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popov</surname><given-names>S</given-names></name><name><surname>Rexach</surname><given-names>M</given-names></name><name><surname>Ratner</surname><given-names>L</given-names></name><name><surname>Blobel</surname><given-names>G</given-names></name><name><surname>Bukrinsky</surname><given-names>M</given-names></name></person-group><article-title>Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>13347</fpage><lpage>13352</lpage><pub-id pub-id-type="pmid">9582382</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.21.13347</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popov</surname><given-names>S</given-names></name><name><surname>Rexach</surname><given-names>M</given-names></name><name><surname>Zybarth</surname><given-names>G</given-names></name><name><surname>Reiling</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>MA</given-names></name><name><surname>Ratner</surname><given-names>L</given-names></name><name><surname>Lane</surname><given-names>CM</given-names></name><name><surname>Moore</surname><given-names>MS</given-names></name><name><surname>Blobel</surname><given-names>G</given-names></name><name><surname>Bukrinsky</surname><given-names>M</given-names></name></person-group><article-title>Viral protein R regulates nuclear import of the HIV-1 pre-integration complex</article-title><source>EMBO J</source><year>1998</year><volume>17</volume><fpage>909</fpage><lpage>917</lpage><pub-id pub-id-type="pmid">9463369</pub-id><pub-id pub-id-type="doi">10.1093/emboj/17.4.909</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamata</surname><given-names>M</given-names></name><name><surname>Aida</surname><given-names>Y</given-names></name></person-group><article-title>Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms</article-title><source>J Virol</source><year>2000</year><volume>74</volume><fpage>7179</fpage><lpage>7186</lpage><pub-id pub-id-type="pmid">10888660</pub-id><pub-id pub-id-type="doi">10.1128/JVI.74.15.7179-7186.2000</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>MP</given-names></name><name><surname>de Noronha</surname><given-names>CM</given-names></name><name><surname>Heusch</surname><given-names>MI</given-names></name><name><surname>Greene</surname><given-names>S</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><article-title>Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>1522</fpage><lpage>1532</lpage><pub-id pub-id-type="pmid">11152524</pub-id><pub-id pub-id-type="doi">10.1128/JVI.75.3.1522-1532.2001</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Mikhail</surname><given-names>M</given-names></name><name><surname>Gill</surname><given-names>MJ</given-names></name><name><surname>Beckthold</surname><given-names>B</given-names></name><name><surname>Salemi</surname><given-names>M</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Piller</surname><given-names>SC</given-names></name><name><surname>Saksena</surname><given-names>NK</given-names></name></person-group><article-title>Evidence for host-driven selection of the HIV type 1 vpr gene in vivo during HIV disease progression in a transfusion-acquired cohort</article-title><source>AIDS Res Hum</source><year>2005</year><volume>21</volume><fpage>728</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1089/aid.2005.21.728</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mikhail</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Lemey</surname><given-names>P</given-names></name><name><surname>Beckholdt</surname><given-names>B</given-names></name><name><surname>Vandamme</surname><given-names>AM</given-names></name><name><surname>Gill</surname><given-names>MJ</given-names></name><name><surname>Saksena</surname><given-names>NK</given-names></name></person-group><article-title>Full-length HIV type 1 genome analysis showing evidence for HIV type 1 transmission from a nonprogressor to two recipients who progressed to AIDS</article-title><source>AIDS Res Hum</source><year>2005</year><volume>21</volume><fpage>575</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1089/aid.2005.21.575</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>A</given-names></name><name><surname>Gendelman</surname><given-names>HE</given-names></name><name><surname>Koenig</surname><given-names>S</given-names></name><name><surname>Folks</surname><given-names>T</given-names></name><name><surname>Willey</surname><given-names>R</given-names></name><name><surname>Rabson</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name></person-group><article-title>Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone</article-title><source>J Virol</source><year>1986</year><volume>59</volume><fpage>284</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">3016298</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abramoff</surname><given-names>MD</given-names></name><name><surname>Magelhaes</surname><given-names>PJ</given-names></name><name><surname>Ram</surname><given-names>SJ</given-names></name></person-group><article-title>Image Processing with ImageJ</article-title><source>Biophotonics Int</source><year>2004</year><volume>11</volume><fpage>36</fpage><lpage>42</lpage></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takebe</surname><given-names>Y</given-names></name><name><surname>Motomura</surname><given-names>K</given-names></name><name><surname>Tatsumi</surname><given-names>M</given-names></name><name><surname>Lwin</surname><given-names>HH</given-names></name><name><surname>Zaw</surname><given-names>M</given-names></name><name><surname>Kusagawa</surname><given-names>S</given-names></name></person-group><article-title>High prevalence of diverse forms of HIV-1 intersubtype recombinants in Central Myanmar: geographical hot spot of extensive recombination</article-title><source>AIDS</source><year>2003</year><volume>17</volume><fpage>2077</fpage><lpage>2087</lpage><pub-id pub-id-type="pmid">14502011</pub-id><pub-id pub-id-type="doi">10.1097/00002030-200309260-00009</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>MP</given-names></name><name><surname>de Noronha</surname><given-names>CM</given-names></name><name><surname>Eckstein</surname><given-names>LA</given-names></name><name><surname>Hataye</surname><given-names>J</given-names></name><name><surname>Mundt</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>SA</given-names></name><name><surname>Neidleman</surname><given-names>JA</given-names></name><name><surname>Goldsmith</surname><given-names>MA</given-names></name><name><surname>Greene</surname><given-names>WC</given-names></name></person-group><article-title>Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>7582</fpage><lpage>7589</lpage><pub-id pub-id-type="pmid">12805458</pub-id><pub-id pub-id-type="doi">10.1128/JVI.77.13.7582-7589.2003</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>Y</given-names></name><name><surname>Sanchez</surname><given-names>PV</given-names></name><name><surname>Meyer</surname><given-names>BE</given-names></name><name><surname>Malim</surname><given-names>MH</given-names></name></person-group><article-title>Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>8348</fpage><lpage>8352</lpage><pub-id pub-id-type="pmid">11483780</pub-id><pub-id pub-id-type="doi">10.1128/JVI.75.17.8348-8352.2001</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimpton</surname><given-names>J</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><article-title>Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene</article-title><source>J Virol</source><year>1992</year><volume>66</volume><fpage>2232</fpage><lpage>2239</lpage><pub-id pub-id-type="pmid">1548759</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vodicka</surname><given-names>MA</given-names></name><name><surname>Koepp</surname><given-names>DM</given-names></name><name><surname>Silver</surname><given-names>PA</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name></person-group><article-title>HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection</article-title><source>Genes &#x00026; Development</source><year>1998</year><volume>12</volume><fpage>175</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">9436978</pub-id><pub-id pub-id-type="doi">10.1101/gad.12.2.175</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahalingam</surname><given-names>S</given-names></name><name><surname>Ayyavoo</surname><given-names>V</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Kieber-Emmons</surname><given-names>T</given-names></name><name><surname>Weiner</surname><given-names>DB</given-names></name></person-group><article-title>Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr</article-title><source>J Virol</source><year>1997</year><volume>71</volume><fpage>6339</fpage><lpage>6347</lpage><pub-id pub-id-type="pmid">9261351</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>XJ</given-names></name><name><surname>Subbramanian</surname><given-names>RA</given-names></name><name><surname>Rougeau</surname><given-names>N</given-names></name><name><surname>Boisvert</surname><given-names>F</given-names></name><name><surname>Bergeron</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name></person-group><article-title>Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation</article-title><source>J Virol</source><year>1995</year><volume>69</volume><fpage>7032</fpage><lpage>7044</lpage><pub-id pub-id-type="pmid">7474123</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wagstaff</surname><given-names>KM</given-names></name><name><surname>Dias</surname><given-names>MM</given-names></name><name><surname>Alvisi</surname><given-names>G</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name></person-group><article-title>Quantitative analysis of protein-protein interactions by native page/fluorimaging</article-title><source>Journal of Fluorescence</source><year>2005</year><volume>15</volume><fpage>469</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">16167204</pub-id><pub-id pub-id-type="doi">10.1007/s10895-005-2819-5</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Somasundaran</surname><given-names>M</given-names></name><name><surname>Sharkey</surname><given-names>M</given-names></name><name><surname>Brichacek</surname><given-names>B</given-names></name><name><surname>Luzuriaga</surname><given-names>K</given-names></name><name><surname>Emerman</surname><given-names>M</given-names></name><name><surname>Sullivan</surname><given-names>JL</given-names></name><name><surname>Stevenson</surname><given-names>M</given-names></name></person-group><article-title>Evidence for a cytopathogenicity determinant in HIV-1 Vpr</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>9503</fpage><lpage>9508</lpage><pub-id pub-id-type="pmid">12093916</pub-id><pub-id pub-id-type="doi">10.1073/pnas.142313699</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subbramanian</surname><given-names>RA</given-names></name><name><surname>Kessous-Elbaz</surname><given-names>A</given-names></name><name><surname>Lodge</surname><given-names>R</given-names></name><name><surname>Forget</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>XJ</given-names></name><name><surname>Bergeron</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages</article-title><source>J Exp Med</source><year>1998</year><volume>187</volume><fpage>1103</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">9529326</pub-id><pub-id pub-id-type="doi">10.1084/jem.187.7.1103</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>XJ</given-names></name><name><surname>Mouland</surname><given-names>AJ</given-names></name><name><surname>Subbramanian</surname><given-names>RA</given-names></name><name><surname>Forget</surname><given-names>J</given-names></name><name><surname>Rougeau</surname><given-names>N</given-names></name><name><surname>Bergeron</surname><given-names>D</given-names></name><name><surname>Cohen</surname><given-names>EA</given-names></name></person-group><article-title>Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells</article-title><source>J Virol</source><year>1998</year><volume>72</volume><fpage>4686</fpage><lpage>4693</lpage><pub-id pub-id-type="pmid">9573232</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanitharani</surname><given-names>R</given-names></name><name><surname>Mahalingam</surname><given-names>S</given-names></name><name><surname>Rafaeli</surname><given-names>Y</given-names></name><name><surname>Singh</surname><given-names>SP</given-names></name><name><surname>Srinivasan</surname><given-names>A</given-names></name><name><surname>Weiner</surname><given-names>DB</given-names></name><name><surname>Ayyavoo</surname><given-names>V</given-names></name></person-group><article-title>HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication in vitro</article-title><source>Virology</source><year>2001</year><volume>289</volume><fpage>334</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">11689055</pub-id><pub-id pub-id-type="doi">10.1006/viro.2001.1153</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rey</surname><given-names>F</given-names></name><name><surname>BouHamdan</surname><given-names>M</given-names></name><name><surname>Navarro</surname><given-names>JM</given-names></name><name><surname>Agostini</surname><given-names>I</given-names></name><name><surname>Willetts</surname><given-names>K</given-names></name><name><surname>Bouyac</surname><given-names>M</given-names></name><name><surname>Tamalet</surname><given-names>C</given-names></name><name><surname>Spire</surname><given-names>B</given-names></name><name><surname>Vigne</surname><given-names>R</given-names></name><name><surname>Sire</surname><given-names>J</given-names></name></person-group><article-title>A role for human immunodeficiency virus type 1 Vpr during infection of peripheral blood mononuclear cells</article-title><source>J Gen Virol</source><year>1998</year><volume>79</volume><fpage>1083</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">9603322</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altfeld</surname><given-names>M</given-names></name><name><surname>Addo</surname><given-names>MM</given-names></name><name><surname>Eldridge</surname><given-names>RL</given-names></name><name><surname>Yu</surname><given-names>XG</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Khatri</surname><given-names>A</given-names></name><name><surname>Strick</surname><given-names>D</given-names></name><name><surname>Phillips</surname><given-names>MN</given-names></name><name><surname>Cohen</surname><given-names>GB</given-names></name><name><surname>Islam</surname><given-names>SA</given-names></name><name><surname>Kalams</surname><given-names>SA</given-names></name><name><surname>Brander</surname><given-names>C</given-names></name><name><surname>Goulder</surname><given-names>PJ</given-names></name><name><surname>Rosenberg</surname><given-names>ES</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Collaboration</surname><given-names>HIVS</given-names></name></person-group><article-title>Vpr is preferentially targeted by CTL during HIV-1 infection</article-title><source>J Immunol</source><year>2001</year><volume>167</volume><fpage>2743</fpage><lpage>2752</lpage><pub-id pub-id-type="pmid">11509618</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altfeld</surname><given-names>MA</given-names></name><name><surname>Trocha</surname><given-names>A</given-names></name><name><surname>Eldridge</surname><given-names>RL</given-names></name><name><surname>Rosenberg</surname><given-names>ES</given-names></name><name><surname>Phillips</surname><given-names>MN</given-names></name><name><surname>Addo</surname><given-names>MM</given-names></name><name><surname>Sekaly</surname><given-names>RP</given-names></name><name><surname>Kalams</surname><given-names>SA</given-names></name><name><surname>Burchett</surname><given-names>SA</given-names></name><name><surname>McIntosh</surname><given-names>K</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><name><surname>Goulder</surname><given-names>PJ</given-names></name></person-group><article-title>Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay</article-title><source>J Virol</source><year>2000</year><volume>74</volume><fpage>8541</fpage><lpage>8549</lpage><pub-id pub-id-type="pmid">10954555</pub-id><pub-id pub-id-type="doi">10.1128/JVI.74.18.8541-8549.2000</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bieniasz</surname><given-names>PD</given-names></name></person-group><article-title>Intrinsic immunity: a front-line defense against viral attack</article-title><source>Nat Immunol</source><year>2004</year><volume>5</volume><fpage>1109</fpage><lpage>1115</lpage><pub-id pub-id-type="pmid">15496950</pub-id><pub-id pub-id-type="doi">10.1038/ni1125</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Dyer</surname><given-names>WB</given-names></name><name><surname>Zaunders</surname><given-names>JJ</given-names></name><name><surname>Mikhail</surname><given-names>M</given-names></name><name><surname>Sullivan</surname><given-names>JS</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Haddad</surname><given-names>DN</given-names></name><name><surname>Harris</surname><given-names>G</given-names></name><name><surname>Holt</surname><given-names>JA</given-names></name><name><surname>Cooper</surname><given-names>DA</given-names></name><name><surname>Miranda-Saksena</surname><given-names>M</given-names></name><name><surname>Boadle</surname><given-names>R</given-names></name><name><surname>Kelleher</surname><given-names>AD</given-names></name><name><surname>Saksena</surname><given-names>NK</given-names></name></person-group><article-title>Comprehensive analyses of a unique HIV-1-infected nonprogressor reveal a complex association of immunobiological mechanisms in the context of replication-incompetent infection</article-title><source>Virology</source><year>2002</year><volume>304</volume><fpage>246</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">12504566</pub-id><pub-id pub-id-type="doi">10.1006/viro.2002.1706</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>RY</given-names></name><name><surname>Bukrinsky</surname><given-names>M</given-names></name><name><surname>Elder</surname><given-names>RT</given-names></name></person-group><article-title>HIV-1 viral protein R (Vpr) &#x00026; host cellular responses</article-title><source>Indian J Med Res</source><year>2005</year><volume>121</volume><fpage>270</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">15817944</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Molecular characterization of the HIV type 1 vpr gene in infected Chinese former blood/plasma donors at different stages of diseases</article-title><source>AIDS Res Hum Retroviruses</source><year>2008</year><volume>24</volume><fpage>661</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">18366311</pub-id><pub-id pub-id-type="doi">10.1089/aid.2007.0270</pub-id></citation></ref></ref-list></back></article> 